RCPT up -0.32% percent Today $RCPT High is at 110.94 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 4:07 PM

RCPT up -0.32% percent Today $RCPT High is at 110.94 and the Low 107.52 with current volume of 207,328.

Recent News posted below.

Receptos Inc RCPT other info.
http://investorshangout.com/Receptos-Inc-RCPT-87962/

RCPT Receptos Inc Recent Headline News

Receptos to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Thu Nov 06, 3:03PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Credit Suisse Healthcare Conference at The Biltmore Hotel in Phoenix, Arizona. The presentation is scheduled for Wednesday, November 12 at 8:30am. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 108.79 (-0.68)

Receptos' (RCPT) CEO Faheem Hasnain on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 11:46AM CST

RCPT: 108.79 (-0.68)

Receptos posts 3Q loss
Automated Insights - Tue Nov 04, 7:19AM CST
SAN DIEGO (AP) _ Receptos Inc. (RCPT) on Tuesday reported a loss of $32.2 million in its third quarter.
RCPT: 108.79 (-0.68)

Receptos misses by $0.23, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:04AM CST

RCPT: 108.79 (-0.68)

Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease -
RCPT: 108.79 (-0.68)

Receptos to Present at Nomura BioPharma Conference
GlobeNewswire - Mon Nov 03, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Nomura BioPharma Conference at the Mandarin Oriental Hotel in Boston. The presentation is scheduled for Thursday, November 6 at 2:15pm Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 108.79 (-0.68)

Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 44.21 (+0.12), WMGI: 28.15 (+0.18), CFN: 57.49 (-0.03), UTHR: 123.94 (-1.23), RCPT: 108.79 (-0.68), WMGIZ: 4.42 (+0.06)

Receptos to Hold Third Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 4 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
RCPT: 108.79 (-0.68)

Receptos (RCPT) Worth Watching: Stock Moves Up 41.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:39AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as its shares rose over 41% on the day.
LCI: 49.97 (-1.84), PTLA: 27.34 (-0.31), RCPT: 108.79 (-0.68), IG: 9.67 (+0.05)

Nasdaq stocks posting largest percentage increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
VDSI: 27.56 (-0.71), ECHO: 28.11 (+0.16), LAYN: 7.52 (-0.16), NVAX: 5.30 (+0.09), SCYX: 9.52 (-0.15), RCPT: 108.79 (-0.68), TRNX: 26.04 (+0.05), IDTI: 17.94 (-0.17), SANM: 25.54 (+0.15)

Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.53 (+0.18), KSS: 56.20 (-0.37), MU: 33.22 (+0.13), PFE: 30.30 (+0.10), HAL: 53.78 (+0.15), AMGN: 162.39 (-0.70), NQ: 7.59 (+0.10), RGC: 22.19 (-0.41), MS: 35.80 (-0.08), MSG: 74.52 (-0.16), NVAX: 5.30 (+0.09), CQB: 14.44 (unch), SRPT: 15.61 (-0.43), RCPT: 108.79 (-0.68), TWTR: 39.60 (+0.01), PTIE: 1.66 (-0.04)

Health Care Stocks On The Rise With Help From 3 Stocks
at The Street - Tue Oct 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
AMGN: 162.39 (-0.70), RCPT: 108.79 (-0.68), NVS: 92.77 (+0.14)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:46AM CDT

RGSE: 0.81 (-0.06), AMKR: 6.53 (+0.18), VTAE: 16.58 (+0.19), ASTI: 2.06 (+0.12), CLF: 10.81 (-0.23), LMNX: 18.45 (+0.10), IDTI: 17.94 (-0.17), HNR: 3.10 (+0.08), VDSI: 27.56 (-0.71), DCO: 25.21 (+1.41), MDCO: 24.30 (-0.06), SCYX: 9.52 (-0.15), VGGL: 1.61 (+0.01), RCPT: 108.79 (-0.68), IBIO: 1.14 (-0.09), SNY: 47.10 (+0.91), TWTR: 39.60 (+0.01), DPW: 1.69 (+0.06), MERU: 4.00 (-0.04), SANM: 25.54 (+0.15)

Receptos Soars After Lead Drug Racks Up Another Win
at Investor's Business Daily - Tue Oct 28, 10:46AM CDT
Receptos (RCPT) stock jumped more than 47% to a new high above 99 in morning trading on the stock market today, and the company got multiple price-target increases after its bowel-disease drug succeeded in a midstage trial. Receptos announced late...
JNJ: 108.80 (-0.02), RCPT: 108.79 (-0.68), ABBV: 63.78 (-0.01)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 8:13AM CDT

KSS: 56.20 (-0.37), FRO: 1.35 (-0.03), ASTI: 2.06 (+0.12), TRNX: 26.04 (+0.05), CVLT: 49.54 (+1.19), UBS: 17.34 (+0.23), BWLD: 162.54 (+3.31), HASI: 13.67 (-0.09), COH: 34.28 (+0.38), VDSI: 27.56 (-0.71), MSG: 74.52 (-0.16), NVO: 44.34 (+1.04), ACI: 2.43 (-0.08), RCPT: 108.79 (-0.68), TWTR: 39.60 (+0.01), SNY: 47.10 (+0.91), FOLD: 6.12 (-0.08), NE: 21.29 (+0.14)

Stock Futures Positive, Steady; Vasco Rockets, Twitter Fades
at Investor's Business Daily - Tue Oct 28, 8:01AM CDT
Stock futures rolled up moderate gains ahead of Tuesday's open, as investors geared up for a session with many moving parts. Dow futures were steady, trading 73.1 points above fair market value. Nasdaq 100 futures were up a strong 19.4 points, and...
WHR: 174.90 (+1.11), VDSI: 27.56 (-0.71), RCPT: 108.79 (-0.68), BP: 41.76 (-0.10), TWTR: 39.60 (+0.01), AET: 84.57 (+0.55)

Receptos up premarket on UC trial results
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 7:09AM CDT

RCPT: 108.79 (-0.68)

RECEPTOS
at Investor's Business Daily - Mon Oct 27, 5:48PM CDT
RECEPTOS (RCPT), a biotech, reported positive phase 2 trial results for its RPC1063 treatment for ulcerative colitis. Shares shot up 25.1% to 85.02.
RCPT: 108.79 (-0.68)

Receptos lead product successful in Phase 2 for UC at higher dose
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 5:25PM CDT

RCPT: 108.79 (-0.68)

Receptos Inc. (RCPT) Stock Research Links

RCPT Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kate Layman's Dual Board Roles Enhance Community Links

Marking Milestones Amid Strategic Shifts What a way to celebrate a two-year anniversary! Kate Layman, founder of M.C. Layman, hits this milestone head-on, not just by steering her company into its third year but also by snagging leadership roles in two significant community organizations in Frederick County, Maryland. You know what's rare today? Executives who don't just...

Shenzhen Media Push: Shaping Asia-Pacific's Future

A Metamorphosis in Shenzhen You ever hear about a place that rockets from obscurity to global significance in the blink of an eye? Well, Shenzhen, China is that place. Forty years ago, it was just a quaint fishing village. Fast forward a few decades, and you've got yourself an international powerhouse—a testament to China's rapid development strategy. Shenzhen is now...

Signant and Lothar Forge Future in Clinical Trials

Breathing New Life into Clinical Trials Alright, folks, listen up. We've got a fresh collaboration cooking that could shake things up in the clinical trial sector. Signant Health, a heavyweight in clinical trial solutions, has teamed up with Lothar Medical, and they’ve hitched their wagons to launch something rather intriguing: the ALDS PRO pulmonary function tech. Let...

Pathlock Faces Identity Governance Opportunities in 2026

Challenges in Identity Governance Emerge for 2026 Imagine a world where digital identities run wild—unmonitored, orphaned, dormant. Welcome to 2026, where identity governance and administration (IGA) face a reckoning, dragging enterprises into the spotlight as they scramble to protect against identity chaos. With Pathlock’s recent recognition in the Gartner Market...

AI: Game-Changer for IT Budgets & Productivity Gains

AI's Potential to Transform IT Operations You ever feel like IT departments are just stuck on repeat, burning through cash and time just to keep the lights on? It's a common gripe, and Info-Tech Research Group's latest blueprint drives this home, highlighting that routine IT chores eat up a staggering 83% of budgets and 66% of staff's ticking hourglass. Now, who wouldn't...

Hisense Showcases AI in Everyday Living at IFA 2026

Hisense's Vision: An AI Utopia for Home Take this in: Hisense is cooking something bold at IFA 2026. They're pushing the envelope by integrating AI into our daily grind, promising to change the way we interact with the spaces that matter most. No more just dreaming about futuristic homes—these guys seem dead set on making them our everyday reality. Connected...

Local Climate Resilience Gains Urgency in the Southwest

Local Impact Means Taking Climate Change Personally If you haven't felt it yet, you will. Climate change isn't just a global headline anymore—it's a daily reality that’s reshaping life where you stand. David W. DuBois, New Mexico's top climatologist, is sounding the alarm this time on the new Net Zero Speaks episode, saying it's on us to use local climate knowledge to...

Datavault AI Sued: Investor Rights and Implications

Datavault AI in Hot Water: What Happened? When you've been watching markets as long as I have, you learn to spot trouble quicker than a cat on a hot tin roof. Datavault AI Inc., or DVLT as they’re known on NASDAQ, is feeling the heat after some revelations that could peel the paint off a wall. They're under the microscope for allegedly misleading investors about their...

Halloween 2026: Gemmy's Animatronics Add Thrills

Halloween's New Twist with Gemmy's Animatronics Well, just when you thought Halloween couldn't get any more over the top, here comes Gemmy with their 3-foot tall animatronic characters ready to give your trick-or-treat scene that extra jolt. These aren't just any run-of-the-mill decorations. Nope, they come with a twist—an industrial-strength twist of scares and sweets...

Woodland Direct Expands West with Reno Facility

Woodland Direct Takes a Bold Step Westward It's no small feat when a company's growing pains turn into growing gains, yet that's exactly what Woodland Direct has managed to pull off with their latest expansion strategy. The Auburn Hills-based e-commerce juggernaut, synonymous with high-quality fire products, just cut the ribbon on a sparkling new 47,000-square-foot...